Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin versus placebo for stress reduction in adults with autism
2025-524797-42-00Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Oxytocin with Placebo (2 arms). Planned start Nov 2026; status: authorised.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2025-524797-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524797-42-00.